The expression of CXCR3 was tested by qPCR with clinical samples from adenocarcinoma patients and normal endometrium from patients with other diseases that need to remove the uterus to identify the effect of CXCR3 (Fig. 9C), indicating that the expression of CXCR3 was lower in endometrial adenocarcinoma. This evidence concerns the gene CXCR3 and adenocarcinoma.